The 30-day study on cravings and neurocognition was designed as a follow-up to Dr. Urschel’s 90-day open-label study on the effects of the PROMETA Treatment Program in treatment-seeking, methamphetamine-dependent subjects.
Research Across America conducted an open-label study of 50 people to evaluate the clinical effectiveness and safety of the PROMETA® Treatment Program for treating the methamphetamine- dependant population.
Terrence Nolan still remembers the first time he got drunk. "I was 12 years old, in junior high school, and some older friends of mine got hold of some hard liquor," Nolan recalled. Read the full article on DailyBreeze.com.
* Clinical studies are under way to evaluate the PROMETA® Treatment Program and to confirm reports from physicians using the PROMETA Treatment Program in their practices. Only a physician licensed to treat with the PROMETA Treatment Program can determine if they are appropriate for any individual patient. The medications used in the PROMETA Treatment Program are Food and Drug Administration (FDA) approved for uses other than treating dependence on alcohol, cocaine or methamphetamine. Therefore, the risks and benefits of using these medications to treat dependence on these substances have not been evaluated by the FDA.
The information provided herein is for general education purposes only and is not medical advice. Hythiam does not provide treatment or make treatment recommendations. Hythiam does not practice medicine or provide medical care to patients.
